Molecular Biologic Staging of Lung Cancer

Annals of Thoracic Surgery

Volumn 85, Issue 2, 2008, Pages

  D'Amico, Thomas A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; GENOMICS; HAZARD RATIO; HUMAN; IN SITU HYBRIDIZATION; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT FAILURE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-1; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 38349148694     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.11.047     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., et al. Cancer statistic, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
3. Rami-Porta R., Ball D., Crowley J., et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2 (2007) 593-602
4. Postmus P., Brambilla E., Chansky K., et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2 (2007) 686-693
5. Goldstraw P., Crowley J., Chansky K., et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification for malignant tumors. J Thorac Oncol 2 (2007) 706-714
6. Ettinger D.S., Bepler G., Bueno R., et al. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 548-582
7. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
8. Strauss G.M., Herndon J., Maddus A., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol (2004) abstract 7019
9. Winton T.L., Livingston R., Johnson D., et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non-small-cell lung cancer (NSCLC) intergroup JBR 10. Proc Am Soc Clin Oncol (2004) abstract 7018
10. D'Cunha J., Corfits A.L., Herndon II J.E., et al. Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer-preliminary results of cancer and leukemia group B trial 9761. J Thorac Cardiovasc Surg 123 (2002) 484-491
11. Chen G., Gharib T.G., Wang H., et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Nat Acad Sci USA 100 (2003) 13537-13542
12. Granville C.A., and Dennis P.A. An overview of lung cancer genomics and proteomics. Am J Respir Cell Molec Biol 32 (2005) 169-176
13. D'Amico T.A., Massey M., Herndon J.E., et al. A biological risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
14. D'Amico T.A., Aloia T.A., Herndon J.E., et al. Molecular biologic substaging in patients with stage I non-small cell lung cancer: Risk stratification according to gender and histologic subtype. Ann Thorac Surg 69 (2000) 882-886
15. Harpole Jr. D.H., Herndon II J.E., Wolfe W.G., Iglehart J.D., and Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55 (1995) 51-56
16. Brooks K.R., To K., Moore-Joshi M., et al. Measurement of chemotherapy resistance markers in patients with stage III non-small cell lung cancer: a novel approach to patient selection. Ann Thorac Surg 76 (2003) 187-193
17. Lau C.L., D'Amico T.A., and Harpole D.H. Staging and prognosis: clinical and molecular prognostic factors and models for non-small cell lung cancer. In: Pass H.I., Mitchell J.B., Johnson D.H., Turrisi A.T., and Minna J.D. (Eds). Lung cancer principles and practice. 2nd ed (2000), Lippincott, Williams and Wilkins, Philadelphia, PA 612-627
18. Kern J.A., Schwartz D.A., Nordberg J.E., et al. P185neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res 50 (1990) 5184-5187
19. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 58 (2004) 991-1002
20. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22 (2004) 777-784
21. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 22 (2004) 785-794
22. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE-a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (2004) abstract 7011
23. Gatzemeier U., Pluzanska A., Szezesna A., et al. Results of a phase III trial of erlotinib (OSI-744) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (2004) abstract 7010
24. Shepherd F.A., Pereira J., Ciuleanu T.E., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol (2004) abstract 7022
25. Langer C.J., Stephenson P., Thor A., Vangel M., and Johnson D.H. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 22 (2004) 1180-1187
26. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Onc 15 (2004) 19-27
27. Schlaeppi J.M., and Wood J.M. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Can Met Reviews 18 (1999) 473-481
28. Hurwitz H., Fehrenbacher L., Cartwright T., et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol (2003) 22a [abstract 3646]
29. DeVore R.F., Fehrenbacher L., Herbst R.S., et al. A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19 (2000) 485a [abstract 1896]
30. Johnson D.H., DeVore R., Kabbinavar F., et al. Carboplatin (C) + paclitaxel (P) + rhuMab-VEGF(AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 20 (2001) 315a [abstract 1256]
31. Yanagisawa K., Xu B.J., Carbone D.P., and Caprioli R.M. Molecular fingerprinting in human lung cancer. Clin Lung Cancer 5 (2003) 113-118
32. Miura K., Bowman E.D., Simon R., et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 62 (2002) 3244-3250
33. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
34. Hoang C.D., D'Cunha J., Tawfic S.H., Gruessner A.C., Kratzke R.A., and Maddaus M.A. Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. J Thorac Cardiovasc Surg 127 (2004) 1332-1342
35. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 (2006) 570-580
36. Dressman H.K., Berchuck A., Chan G., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25 (2007) 517-525
37. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 (2006) 1294-1300
38. Hsu D.S., Balakumaran B.S., Acharya C.R., et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25 (2007) 4350-4357